Clinical Trial Update: A Phase II Trial to Explore Niraparib and Anlotinib Maintenance Retreatment in Platinum-Sensitive Recurrent Ovarian Cancer Patients Previously Treated With PARPi [Phase 2]

View source ↗

Summary

Phase II trial evaluating niraparib and anlotinib as maintenance retreatment in platinum-sensitive recurrent ovarian cancer after prior PARP inhibitor therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Niraparib (Niraparib)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Epithelial Ovarian Cancer | Phase 2 | Status: UNKNOWN